Novel liposomal formulations for protection and delivery of levodopa: Structure-properties correlation.

Antiradical activity Intranasal delivery Levodopa Liposomes N-oxide moiety Parkinson’s disease

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
25 Aug 2023
Historique:
received: 21 04 2023
revised: 11 07 2023
accepted: 13 07 2023
medline: 21 8 2023
pubmed: 17 7 2023
entrez: 16 7 2023
Statut: ppublish

Résumé

Liposomes are promising drug carriers for a wide range of central nervous system disorders, such as Parkinson's disease (PD), since they can protect active substances from degradation and could be administered intranasally, ensuring a direct access to the brain. Levodopa (LD), the drug commonly used to treat PD, spontaneously oxidizes in aqueous solutions and thus needs to be stabilized. Our investigation focuses on the preparation and the physico-chemical characterization of mixed liposomes to vehiculate LD and two natural substances (L-ascorbic acid and quercetin) that can prevent its oxidation and contribute to the treatment of Parkinson's disease. These co-loaded vesicles were prepared using a saturated phospholipid and structurally related cationic or analogue N-oxide surfactants and showed different properties, based on their composition. In particular, ex-vivo permeability tests using porcine nasal mucosa were performed, denoting that subtle variations of the lipids structure can significantly affect the delivery of LD to the target site.

Identifiants

pubmed: 37454830
pii: S0378-5173(23)00650-6
doi: 10.1016/j.ijpharm.2023.123230
pii:
doi:

Substances chimiques

Levodopa 46627O600J
Liposomes 0
Drug Carriers 0
Ascorbic Acid PQ6CK8PD0R

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

123230

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Elena Allegritti (E)

Dipartimento di Scienze Fisiche e Chimiche, Università degli Studi dell'Aquila, Via Vetoio, 67010 Coppito, AQ, Italy.

Sara Battista (S)

Dipartimento di Scienze Fisiche e Chimiche, Università degli Studi dell'Aquila, Via Vetoio, 67010 Coppito, AQ, Italy.

Maria Anna Maggi (MA)

Hortus Novus, Via Campo Sportivo 2, Canistro, 67051 L'Aquila, Italy.

Claudia Marconi (C)

Dipartimento di Chimica, Università di Roma "Sapienza", Piazzale Aldo Moro 5, 00185 Roma, Italy.

Luciano Galantini (L)

Dipartimento di Chimica, Università di Roma "Sapienza", Piazzale Aldo Moro 5, 00185 Roma, Italy.

Luisa Giansanti (L)

Dipartimento di Scienze Fisiche e Chimiche, Università degli Studi dell'Aquila, Via Vetoio, 67010 Coppito, AQ, Italy. Electronic address: luisa.giansanti@univaq.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH